We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Medical sector earnings have been strong, with major biotech firms beating estimates.\",\"1\":\"Zevra, Inovio and Journey Medical show positive ESP and are set to report on Aug. 12.\",\"2\":\"Product launches, FDA approvals and strong cash positions boost these biotech players.\"}
As we near the end of the ongoing earnings season, the scorecard for the Medical sector appears pretty decent. The sector primarily comprises pharma/biotech and medical device companies. Almost all the large biotech companies have already reported second-quarter earnings, which have been pretty good.
Gilead Sciences, Inc. ((GILD - Free Report) ) posted better-than-expected second-quarter 2025 results and upped its annual guidance. Amgen’s second-quarter results were strong as it beat on both earnings and sales and raised its revenue and earnings outlook for 2025. Regeneron, too, beat on earnings and sales, which was encouraging, and managed to post year-over-year revenue growth despite declining sales of lead drug Eylea. Biogen’s second-quarter results were strong as well, as its top and bottom-line figures beat estimates. The company upped its full-year 2025 guidance.
Zeroing in on Winners
Even though most of the companies from the biotech sector have already announced results, there are a few due to report. Some of them seem poised to surpass estimates for the quarter. Here we have highlighted three biotech companies, which are expected to deliver an earnings surprise in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
3 Biotech Stocks That Match the Criteria
Zevra Therapeutics ((ZVRA - Free Report) ), a commercial-stage company, is focused on providing therapies for rare diseases. The FDA approval of Miplyffa (arimoclomol), an orally delivered treatment for Niemann-Pick disease type C (NPC), has strengthened ZVRA’s portfolio. The initial uptake has been strong. Zevra recently submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of NPC. In April 2025, Zevra sold its Pediatric Rare Disease Priority Review Voucher (“PRV”) for gross proceeds of $150 million, which has strengthened its cash position. ZVRA’s other commercial stage asset, Olpruva (sodium phenylbutyrate) for oral suspension, is approved by the FDA for the treatment of certain urea cycle disorders.
The Zacks Consensus Estimate for second-quarter EPS is pegged at $1.43. Zevra is scheduled to report second-quarter earnings on Aug. 12, 2025. The stock has risen 44.2% so far this year.
Zevra Therapeutics, Inc. Price, Consensus and EPS Surprise
Inovio Pharmaceuticals, Inc. ((INO - Free Report) ) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV associated diseases, cancer and infectious diseases. The company’s lead pipeline candidate, INO-3107, is being developed for the treatment of recurrent respiratory papillomatosis, a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. INO is currently on track to begin a rolling submission of the biologics license application (BLA) shortly and request priority review, with a goal of receiving file acceptance by the FDA by the end of 2025.
INO has an Earnings ESP of +10.76% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter loss per share is pinned at 63 cents. INO is scheduled to report second-quarter earnings on Aug. 12, 2025. Inovio beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 18.53%.
Inovio Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Journey Medical Corporation ((DERM - Free Report) ) is a commercial-stage pharmaceutical company that primarily focuses on selling and marketing pharmaceutical products for the treatment of dermatological conditions. DERM markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The launch of Emrosi, its best-in-class oral rosacea treatment, is off to a strong start.
DERM has an Earnings ESP of +14.29% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter loss is pegged at 7 cents per share.
Journey Medical Corporation Price, Consensus and EPS Surprise
DERM beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 44.36%. Journey Medical is scheduled to report second-quarter results on Aug. 12, 2025.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Key Takeaways
As we near the end of the ongoing earnings season, the scorecard for the Medical sector appears pretty decent. The sector primarily comprises pharma/biotech and medical device companies. Almost all the large biotech companies have already reported second-quarter earnings, which have been pretty good.
Gilead Sciences, Inc. ((GILD - Free Report) ) posted better-than-expected second-quarter 2025 results and upped its annual guidance. Amgen’s second-quarter results were strong as it beat on both earnings and sales and raised its revenue and earnings outlook for 2025. Regeneron, too, beat on earnings and sales, which was encouraging, and managed to post year-over-year revenue growth despite declining sales of lead drug Eylea. Biogen’s second-quarter results were strong as well, as its top and bottom-line figures beat estimates. The company upped its full-year 2025 guidance.
Zeroing in on Winners
Even though most of the companies from the biotech sector have already announced results, there are a few due to report. Some of them seem poised to surpass estimates for the quarter. Here we have highlighted three biotech companies, which are expected to deliver an earnings surprise in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
3 Biotech Stocks That Match the Criteria
Zevra Therapeutics ((ZVRA - Free Report) ), a commercial-stage company, is focused on providing therapies for rare diseases. The FDA approval of Miplyffa (arimoclomol), an orally delivered treatment for Niemann-Pick disease type C (NPC), has strengthened ZVRA’s portfolio. The initial uptake has been strong. Zevra recently submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of NPC. In April 2025, Zevra sold its Pediatric Rare Disease Priority Review Voucher (“PRV”) for gross proceeds of $150 million, which has strengthened its cash position. ZVRA’s other commercial stage asset, Olpruva (sodium phenylbutyrate) for oral suspension, is approved by the FDA for the treatment of certain urea cycle disorders.
ZVRA has an Earnings ESP of +58.04% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for second-quarter EPS is pegged at $1.43. Zevra is scheduled to report second-quarter earnings on Aug. 12, 2025. The stock has risen 44.2% so far this year.
Zevra Therapeutics, Inc. Price, Consensus and EPS Surprise
Zevra Therapeutics, Inc. price-consensus-eps-surprise-chart | Zevra Therapeutics, Inc. Quote
Inovio Pharmaceuticals, Inc. ((INO - Free Report) ) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV associated diseases, cancer and infectious diseases. The company’s lead pipeline candidate, INO-3107, is being developed for the treatment of recurrent respiratory papillomatosis, a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. INO is currently on track to begin a rolling submission of the biologics license application (BLA) shortly and request priority review, with a goal of receiving file acceptance by the FDA by the end of 2025.
INO has an Earnings ESP of +10.76% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter loss per share is pinned at 63 cents. INO is scheduled to report second-quarter earnings on Aug. 12, 2025. Inovio beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 18.53%.
Inovio Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Inovio Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Inovio Pharmaceuticals, Inc. Quote
Journey Medical Corporation ((DERM - Free Report) ) is a commercial-stage pharmaceutical company that primarily focuses on selling and marketing pharmaceutical products for the treatment of dermatological conditions. DERM markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The launch of Emrosi, its best-in-class oral rosacea treatment, is off to a strong start.
DERM has an Earnings ESP of +14.29% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter loss is pegged at 7 cents per share.
Journey Medical Corporation Price, Consensus and EPS Surprise
Journey Medical Corporation price-consensus-eps-surprise-chart | Journey Medical Corporation Quote
DERM beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 44.36%. Journey Medical is scheduled to report second-quarter results on Aug. 12, 2025.